Bavarian Nordic A/S

BAVA

DK0015998017

Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%). Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bavarian Nordic A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

147.4 DKK

Average target price

264.8 DKK

Spread / Average Target

+79.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAVARIAN NORDIC A/S	-16.96%	1.63B
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:59 2024-04-19 am EDT			5-day change	1st Jan Change
147.4 ^DKK	+0.41%		-2.22%	-16.96%

Mar. 13	Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults	MT
Mar. 13	Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland	CI

Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults	Mar. 13	MT
Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland	Mar. 13	CI
Nordic Shares Moved Upward Wednesday; BoneSupport Holding Topped Leaders	Mar. 06	DJ
Transcript : Bavarian Nordic A/S, 2023 Earnings Call, Mar 06, 2024	Mar. 06
Bavarian Nordic A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Nordic stocks fell Tuesday, with the OMX Nordic 40 Index declining 0.2%.	Feb. 27	DJ
Transcript : Bavarian Nordic A/S - Analyst/Investor Day	Feb. 26
Bavarian Nordic Receives Accelerated Assessment Status for Chikungunya Vaccine	Feb. 23	MT
Bavarian Nordic A/S Announces Accelerated Assessment for the Upcoming Marketing Authorisation Application for CHIKV VLP	Feb. 23	CI
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	Feb. 21	MT
Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024	Feb. 21	CI
Nordic Stocks Rose Friday; Bavarian Nordic Topped Leaders	Dec. 22	DJ
Stigma, regulatory barriers delay mpox response in country that needs it most	Dec. 05	RE
Nordic Shares Closed Up Monday; Better Collective Topped Leaders	Nov. 20	DJ
Nordic Shares Closed Down Thursday; Better Collective Fell Furthest	Nov. 16	DJ
Transcript : Bavarian Nordic A/S, Q3 2023 Earnings Call, Nov 16, 2023	Nov. 16
Bavarian Nordic Confirms FY23 Revenue Growth Outlook	Nov. 16	MT
Bavarian Nordic A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023	Nov. 16	CI
Bavarian Nordic Wins US Regulatory Nod for Mpox Vaccine in Adults	23-10-26	MT
US CDC panel recommends Bavarian Nordic's vaccine for adults at risk of mpox	23-10-25	RE
Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk	23-10-25	CI
Nordic Shares Decreased Tuesday; Beijer Ref Series B Posted Biggest Loss	23-09-19	DJ
Bavarian Nordic Receives EUR11 Million Smallpox Vaccine Contract	23-09-13	MT
Bavarian Nordic A/S Wins Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve	23-09-13	CI